Biotech | February 26, 2026
Gilead to acquire Arcellx in $7.8 billion bet on next-generation CAR T therapy
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
Under the terms, Arcellx shareholders received $115 per share in cash plus a non-transferable contingent value right
Subscribe To Our Newsletter & Stay Updated
